29 Oct Exploration of the Risk of Suicidality and Self-Harm With GLP-1 Receptor Agonists: A Critical Appraisal
Posted at 11:34h
in
Exploration of the Risk of Suicidality and Self-Harm With GLP-1 Receptor Agonists: A Critical Appraisal
HC0087
Overview
Background
- Safety concerns about the use of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have recently been raised, including a potential increased risk of self-harm and suicidal ideation.
Objectives
- The aim of this project is to conduct a critical appraisal of the available real-world evidence to evaluate the association between GLP-1 RAs and the risk of suicidality and self-harm among patients with type 2 diabetes or obesity.